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OBJECTIVES We sought to determine the effects of oral L-arginine and the hexamethylglutaryl coenzyme
A reductase inhibitor atorvastatin on endothelial function in young patients with type I
diabetes mellitus (DM).
BACKGROUND Endothelial dysfunction, a key early event in atherosclerosis, occurs in young patients with
type I DM, and its reversal may benefit the progression of vascular disease. Cholesterol
reduction in L-arginine improve endothelial function in nondiabetic subjects, but their effect
in patients with type I DM is unknown.
METHODS In a double-blind, 2 3 2 factorial study, we investigated the effect of L-arginine (7 g twice
daily) and atorvastatin (40 mg/day) on conduit artery vascular function in 84 normocholes-
terolemic young adults (mean 6 SD: age 34 years [range 18 to 46], low density lipoprotein
[LDL] cholesterol 2.96 6 0.89 mmol/liter) with type I DM. Brachial artery dilation to flow
(flow-mediated dilation [FMD]) and to the direct smooth muscle dilator glyceryl trinitrate
(GTN) were assessed noninvasively using high resolution ultrasound at baseline and after six
weeks of treatment.
RESULTS Atorvastatin resulted in a 48 6 10% decrease in serum LDL cholesterol levels, whereas
L-arginine levels increased by 247 6 141% after L-arginine therapy. By analysis of covariance,
treatment with atorvastatin resulted in a significant increase in FMD (p 5 0.018. L-Arginine
therapy had no significant effect on endothelial function, and there was no significant change
in dilation to GTN after either intervention.
CONCLUSIONS In young patients with type I DM, improvement in endothelial dysfunction can be
demonstrated after just six weeks of treatment with atorvastatin. In contrast to studies of
hypercholesterolemia, however, L-arginine had no benefit. Treatment with atorvastatin at an
early stage may have an impact on the progression of atherosclerosis in these high risk
patients. (J Am Coll Cardiol 2000;36:410–6) © 2000 by the American College of
Cardiology
Type I diabetes mellitus (DM) is a major risk factor for
premature atherosclerosis, with a cumulative mortality rate
from macrovascular disease as high as 30% by the age of 55
years (1). A key factor in the initiation of the atherosclerotic
process is injury to the vascular endothelium, and endothe-
lial dysfunction has been demonstrated in animal models of
type I DM (2–4) and in young diabetic patients (5–10).
Reversal of endothelial dysfunction, at this early stage, may
therefore retard the development of cardiovascular disease.
An important aspect of endothelial dysfunction in diabe-
tes is reduced bioavailability of endothelium-derived nitric
oxide (NO) (4). The mechanisms that underlie this are
complex and relate to both increased breakdown and de-
creased production of NO (11). Hyperglycemia, activation
of protein kinase C and formation of advanced glycosylation
end products are important sources of oxygen-derived free
radicals (12–14), which accelerate the peroxidation of li-
poproteins (15) and inactivate NO (16,17). In type I DM,
increased susceptibility of low density lipoprotein (LDL) to
oxidation has been reported (18), which may be related to
poor control and duration of diabetes (18,19). Oxidized
LDL has been shown to reduce NO synthase expression
(20), enhance NO breakdown (21) and impair endothelial-
dependent dilation (22). Our recent finding of an inverse
correlation between conduit artery endothelial function and
LDL cholesterol levels is consistent with an important role
for LDL cholesterol in the initiation of diabetic vascular
disease (23). Impaired NO synthesis may also occur in type
I DM as a consequence of glycosylation or impaired
metabolism of its substrate, L-arginine (24,25). A lack of
essential cofactors (26) or alteration in the kinetics of NO
synthase (27) may also decrease NO formation and even
result in the production of superoxide anion (28,29).
In spontaneously diabetic rats, administration of
L-arginine enhances endothelial-dependent dilation
(30,31). L-Arginine therapy has also been shown to improve
endothelial function in subjects with hypercholesterolemia
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(8), and in cholesterol-fed animals, it retards the progression
of atherosclerosis (32). However, few reports have been
published on the effect of L-arginine in patients with type I
DM. We have recently demonstrated that acute adminis-
tration of L-arginine had no beneficial effect on endothelial
function in patients with type I DM, in contrast to its effect
in hypercholesterolemia (33). This suggests potential differ-
ences in the mechanism of endothelial dysfunction between
these risk factor groups, or it may represent the more
complex nature of endothelial function in type I DM. The
benefit of longer term oral administration of L-arginine in
type I DM, or its effect when given in conjunction with
other therapies targeted at restoring endothelial function,
has not been tested.
We hypothesized that cholesterol reduction and
L-arginine therapy may have beneficial and potentially
synergistic effects on endothelial function in patients with
type I DM. We therefore studied the effect of the hexa-
methylglutaryl coenzyme A (HMG-CoA) reductase inhib-
itor atorvastatin, long-term oral L-arginine therapy and their
combination on conduit artery endothelial-dependent dila-
tion in young, clinically well patients with type I DM who
had normal cholesterol levels.
METHODS
Study groups. Subjects aged 18 to 45 years with type I DM
of .2 years duration (range 2 to 41 years) (type I DM
defined as those requiring insulin treatment from diagnosis
and a history of ketoacidosis) and a low density lipoprotein
(LDL) cholesterol level ,4.5 mmol/liter were recruited
from diabetic clinics in London. They were nonsmokers
who had either never smoked or not smoked for .2 years
with a total exposure ,1 pack-year, had a rest supine blood
pressure ,150/90 mm Hg, had no clinical evidence of large
vessel atherosclerosis and were not taking a vasoactive or
cholesterol-lowering medication. Eleven subjects had evi-
dence of background diabetic retinopathy and five had
received treatment for proliferative retinopathy. All subjects
gave informed, written consent, and the local research
Ethics Committee approved the protocol.
Study design. This was a randomized, double-blind, 2 3 2
factorial study. Subjects were randomized to take either
L-arginine, 7 g twice daily, in the form of a lemon-flavored,
sugar-free drink (Pharmacy Manufacturing Unit, Plymouth,
United Kingdom) or placebo equivalent, and atorvastatin,
40 mg/day at night (Parke-Davis Ltd., Eastleigh, United
Kingdom) or placebo. Subjects were thus classified into four
treatment groups taking either two placebos, atorvastatin
plus L-arginine/placebo, L-arginine plus atorvastatin/
placebo or both L-arginine and atorvastatin therapy (Fig. 1).
For both L-arginine and atorvastatin, the active drug and
placebo were packaged identically. Randomization codes
were generated independently (Parke-Davis Ltd.), and each
container was labeled only with the subject’s study number,
which was allocated in a sequential order. The dose of
L-arginine was chosen on the basis of animal experiments
and clinical studies in subjects with hypercholesterolemia, in
whom benefit on endothelial function has previously been
demonstrated (8,34). The subjects were instructed to con-
tinue with their normal diabetic diet and insulin regimen
throughout the study. Endothelium-dependent dilation was
studied noninvasively at baseline and after six weeks of
therapy. Seventy of the 84 subjects were studied in the
morning after an overnight fast. The remaining 14 subjects
were studied in the afternoon after a 6-h fast after their
normal breakfast and morning insulin. All subjects were
studied at the same time of day on both visits. No attempt
was made to study subjects under conditions of euglycemia,
as this would have been logistically difficult, and moreover
would have introduced the potential confounding influence
of a glucose and insulin infusion on endothelial function.
At each visit, venous blood was taken without use of a
tourniquet, for measurement of a full blood count (Bayer
[Technicon] H1 system) and for assay of biochemical
variables by reflectance spectrophotometry (Johnson &
Johnson Vitros dry chemistry system, unless stated other-
wise). Fructosamine (a time-averaged marker that reflects
diabetic control over the preceding 30 days [35]) was
determined from the rate of formation of formazan, using
the Dimension AR system (Roche). Plasma levels of argi-
nine, ornithine, glycine and citruline—amino acids closely
linked to arginine metabolism—were determined after pre-
Abbreviations and Acronyms
CI 5 confidence interval
DM 5 diabetes mellitus
FMD 5 flow-mediated dilation
GTN 5 glyceryl trinitrate
GTN-MD 5 glyceryl trinitrate–mediated dilation
HDL 5 high density lipoprotein
HMG-CoA 5 hexamethylglutaryl coenzyme A
LDL 5 low density lipoprotein
NO 5 nitric oxide
Figure 1. Study protocol. Subjects were randomized to either placebo,
L-arginine (7 g twice daily), atorvastatin (40 mg/day) or combination
therapy. Vascular function was assessed noninvasively at baseline and after
six weeks of treatment.
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cipitation with sulfur salicylic acid, by use of a dedicated ion
exchange amino acid analyzer (Amersham Pharmacia Bio-
tech, Upsala, Sweden). Total and high density lipoprotein
(HDL) cholesterol and triglyceride levels were measured by
reflectance spectrophotometry, and LDL cholesterol was
calculated using the Friedwald formula (36). Subjects were
examined for the presence of microalbuminuria (albumin/
creatinine ratio .2 mg/mmol) from two timed overnight
urine collections.
Assessment of endothelial function. Brachial artery
endothelium-dependent and -independent reactivities were
assessed noninvasively using an accurate and reproducible
high resolution ultrasound technique, as previously de-
scribed (33,37). All scans were performed by the same
operator (A.E.D.). Subjects lay at rest for at least 10 min
before the first scan and remained supine throughout the
procedure. Blood pressure and heart rate were monitored
throughout the study. The right brachial artery was imaged
in a longitudinal section 2 to 10 cm above the elbow, using
a 7-MHz linear-array transducer supported by a stereotactic
clamp and an Acuson 128XP/10 ultrasound system (Acuson
Ltd., Mountain View, California). Blood flow velocity was
measured by pulsed wave Doppler echocardiography, with
the cursor set at 70° to the longitudinal axis of the artery and
the range gate (1.5 mm) in the center of the artery. Brachial
artery diameter was determined using an A-mode tracking
device (Ingenious Systems, the Netherlands), at rest and 55
to 65 s after a brief period of reactive hyperemia induced by
inflating a pneumatic tourniquet placed around the forearm
to 300 mm Hg, with its rapid release after 4.5 min. All scans
were recorded onto super VHS videotape. Hard copy
images of the brachial artery were taken and notes made of
the transducer and arm position, enabling precise reproduc-
tion of conditions and measurement of the same segment of
the artery at subsequent visits. The peak blood flow velocity
and the integral of blood flow velocity over the first 20 s of
reactive hyperemia were determined by pulsed wave Dopp-
ler echocardiography. After a further 10 to 15 min at rest,
sublingual glyceryl trinitrate (GTN) 400 mg, was adminis-
tered, and the response to this endothelium-independent
dilator was assessed after 3 min.
Data analysis. On completion of each study, the stored
radio frequency data for each scan were analyzed by place-
ment of volume sample cursors at the near and far vessel
wall interfaces. Arterial distention was tracked and end-
diastolic diameter determined on a beat-by-beat basis, with
a spatial resolution of 50 mm. All scans were checked by an
independent observer (M.J.M.) who had no knowledge of
the origin of the scan. Scans in which 1) the image at both
studies was not replicated; 2) a satisfactory distensibility
waveform was not achieved; or 3) cursor placement was
incorrect were rejected and excluded from the final analysis.
Vessel dilation in response to flow (flow-mediated dilation
[FMD]) and GTN were expressed as the percent increase in
vessel diameter from baseline. Flow-mediated dilation is
dependent on NO production (38) and correlates with
measures of coronary endothelial function and atheroscle-
rosis (39). Rest volumetric blood flow was calculated for
each study by multiplying the velocity–time integral (cor-
rected for angle) by the heart rate and vessel cross-sectional
area. Although this method may lead to overestimation of
blood flow, inaccuracies are consistent, allowing for a
comparison between visits and individuals.
Statistical analysis. Data are presented as the mean
value 6 SD. The primary outcome measure for this study
was change in FMD, and the secondary outcome measure
was change in GTN–mediated dilation (GTN-MD) be-
tween the two visits. Two-way analysis of covariance was
used to determine the effects of atorvastatin and L-arginine
therapy and their interaction on vascular function. Covari-
ates for age, gender, duration of diabetes, baseline LDL
cholesterol and baseline FMD or GTN-MD were initially
included, as previous studies have indicated that these
variables may have a significant effect on endothelial func-
tion and the response to intervention. Subsequently, covari-
ates for blood pressure, HDL cholesterol, triglycerides,
glucose, fructosamine, total daily insulin dose, vessel size
and the intensity of reactive hyperemia were added to the
model to determine their effect. The effects of L-arginine
and atorvastatin on plasma arginine and lipoprotein sub-
fraction cholesterol levels were compared using the inde-
pendent Student t test. Multiple regression analyses were
used to explore the relations between baseline FMD and
GTN-MD and subject characteristics and risk factor profile.
Initial models were adjusted for age, gender and the
intensity of reactive hyperemia. Subsequently, risk factor
variables (blood pressure, total and LDL and HDL choles-
terol levels and triglyceride levels) and variables related to
diabetic control (glucose level, fructosamine level, total daily
insulin dose, presence of microalbuminuria) were added one
by one to determine whether there was any additional effect.
Statistical significance was inferred at p , 0.05.
RESULTS
Baseline subject characteristics. Eighty-four subjects were
randomized (53 men and 31 women). Age, gender distri-
bution, levels of lipid subfractions, blood pressure and
diabetic characteristics were comparable between the treat-
ment groups and their respective placebo arms (Table 1).
Ten subjects (12%) had microalbuminuria. Seventy-seven
subjects (88%) completed the study, and reasons for with-
drawal are outlined in Table 2. Compliance with the study
drugs was determined from the volume of L-arginine and
the number of tablets of atorvastatin unused on completion
of the study—the rates of which were 87% and 96%,
respectively. Atorvastatin was generally well tolerated, with
no effect on measures of diabetic control. There was no
incidence of muscle pains, increases in creatinine kinase or
transaminase levels. Three subjects taking atorvastatin with-
drew from the study. One subject had an episode of diabetic
ketoacidosis shortly after randomization, related to a routine
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menisectomy; one subject complained of dizziness; and
another subject complained of increased frequency of hypo-
glycemia. Two scans from two subjects were rejected, as
they were technically unsatisfactory (as discussed earlier).
Biochemical effects. Neither L-arginine nor atorvastatin
therapy had a significant effect on fasting glucose concen-
tration, insulin requirements or overall diabetic control, as
determined by fructosamine levels. In the subjects random-
ized to L-arginine, plasma arginine increased from 67 6 15
to 159 6 84 mmol/liter (p , 0.001). L-arginine had no
significant effect on plasma lipid levels or the levels of any of
the other measured amino acids. In subjects randomized to
receive atorvastatin, total, LDL and HDL cholesterol and
triglyceride levels decreased by (mean value 6 SD) 33.3 6
9.4% (p , 0.001), 48.3 6 10% (p , 0.001), 6.1 6 21.3%
(p 5 0.045) and 12.1 6 25.6% (p 5 0.028), respectively.
Effects on vascular function. Baseline vessel size, rest
blood flow, reactive hyperemic blood flow, FMD and
GTN-MD were comparable between the treatment groups
(Table 1). For the whole cohort, FMD and GTN-MD were
3.38 6 3.09% and 17.31 6 7.87%, respectively. The values
for FMD were significantly less than those seen in a
comparable group of nondiabetic subjects previously studied
in our laboratory (9.3 6 3.8%) (23). Baseline FMD was
higher in women than in men. (4.11 6 3.79% vs. 2.97 6
2.56%, p 5 0.1). In the 10 subjects with microalbuminuria,
there was a trend toward a reduction in FMD (3.51 6
3.14% vs. 2.43 6 2.55%, p 5 0.11), as compared with
normoalbuminuric subjects, and a significant reduction in
GTN-MD (17.79 6 8.0% vs. 12.75 6 4.76%, p 5 0.02).
There was a significant correlation between baseline FMD
and hyperemic blood flow velocity over the first 20 s after
release of the tourniquet (r 5 0.23, p 5 0.039), but not with
peak hyperemic blood flow, any of the measured variables of
diabetic control, insulin levels, blood pressure or LDL or
HDL cholesterol or triglyceride levels.
There was no significant change in rest vessel size, blood
flow or reactive hyperemia in response to L-arginine or
atorvastatin therapy. In subjects treated with placebo,
L-arginine alone, atorvastatin alone and combination ther-
apy, FMD changed by 20.34 6 2.11%, 20.33 6 2.49%,
1.75 6 2.88% and 0.68 6 2.45%, respectively. There was no
Table 1. Baseline Characteristics of 84 Subjects With Type I Diabetes Mellitus
Treatment Groups
Placebo L-Arginine Atorvastatin
L-Arginine Plus
Atorvastatin
Male 22 (77%) 21 (72%) 21 (53%) 20 (55%)
Age (yrs) 34.9 6 7.9 35.0 6 6.4 33.7 6 6.1 33.3 6 6.8
Microalbuminuria 4 0 4 2
Duration of diabetes (years) 16.5 6 9.6 15.0 6 9.2 15.1 6 8.5 16.2 6 10.2
Fructosamine (mmol/liter) 408 6 73 374 6 75 427 6 64 414 6 64
Glucose (mmol/liter) 10.8 6 6.2 9.9 6 6.1 10.6 6 5.1 11.4 6 5.1
Daily insulin (IU) 52.8 6 17.4 64.2 6 22.5 53.3 6 25.6 50.5 6 15.6
Arginine (mmol/liter) 57.5 6 15.6 68.9 6 17.6 70.1 6 28.6 65.2 6 12.6
Total cholesterol (mmol/liter) 4.70 6 1.07 4.78 6 0.80 4.92 6 1.07 5.08 6 0.86
LDL cholesterol (mmol/liter) 2.82 6 1.0 2.95 6 0.81 3.08 6 0.92 3.02 6 0.82
HDL cholesterol (mmol/liter) 1.45 6 0.33 1.34 6 0.46 1.47 6 0.37 1.62 6 0.62
Triglycerides (mmol/liter) 0.93 6 0.51 1.09 6 1.08 0.83 6 0.44 0.97 6 0.34
SBP (mm Hg) 122 6 13 127 6 11 122 6 14 120 6 12
DBP (mm Hg) 73 6 7 75 6 8 75 6 9 72 6 6
Rest vessel size (mm) 3.93 6 0.47 4.05 6 0.65 3.69 6 0.70 3.77 6 0.73
FMD (%) 3.49 6 2.99 3.33 6 3.03 3.65 6 3.20 3.01 6 3.32
GTN-MD (%) 17.12 6 8.49 16.44 6 7.49 19.58 6 8.00 16.07 6 7.49
Rest blood flow (ml/min) 83.0 6 48.0 110.6 6 69.7 65.9 6 53.0 86.0 6 61.1
Hyperemic blood flow (AUC)* 75.7 6 26.5 89.3 6 41.9 69.8 6 29.0 78.6 6 35.7
*AUC 5 area under the time–flow curve for hyperemic blood flow over the first 20 s after release of the tourniquet. Data are
presented as the number (%) of patients or mean value 6 SD.
DBP 5 diastolic blood pressure; FMD 5 flow-mediated dilatation; GTN-MD 5 glyceryl trinitrate mediated dilatation;
HDL 5 high-density lipoprotein; LDL 5 low-density lipoprotein; SBP 5 systolic blood pressure.
Table 2. Withdrawals After Randomization
Ref. No. Gender Age (yrs) Treatment Group Reason for Withdrawal
1 F 22 Atorvastatin Ketoacidosis after routine menisectomy
40 F 33 L-arginine Lost to follow-up
42 F 36 Atorvastatin plus L-arginine Lost to follow-up
49 M 41 Placebo Lost to follow-up
53 M 35 Atorvastatin Dizziness
55 F 34 Atorvastatin Episodes of hypoglycemia
78 F 38 Atorvastatin Lost to follow-up
F 5 female; M 5 male.
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evidence of a significant interaction between the effects of
L-arginine and atorvastatin (p 5 0.22), and therefore the
effects of these interventions could be analyzed indepen-
dently. Atorvastatin therapy was associated with a signifi-
cant increase in FMD of 1.26% (95% confidence interval
[CI] 0.22 to 2.30, p 5 0.018), even after allowing for the
effects of baseline FMD and duration of diabetes, which
were the only prespecified baseline covariates that were
significantly associated with a change in FMD (Table 3).
There was no significant change after L-arginine 20.51%
(95% CI: 21.54 to 0.51, p 5 0.32). Other variables,
including total, LDL and HDL cholesterol levels, presence
of microalbuminuria, plasma glucose level, fructosamine
level, total daily insulin dose and blood pressure, were added
to the model, together with interactions between variables
already in the model, but none was found to have a
significant effect. To determine whether changes in other
physiologic variables had influenced the improvement in
endothelial function seen after atorvastatin, the changes in
rest blood flow, reactive hyperemic blood flow and vessel
size were added to the model, but similarly, none had a
significant effect.
No significant association was found between any of the
treatments and GTN-MD (atorvastatin 21.35% [95% CI
27.23 to 4.52]; L-arginine 23.50% [95% CI 29.43 to
2.43]; interaction 25.22% [95% CI 26.58 to 0.51]), indi-
cating that the improvement in FMD seen in the atorva-
statin group is likely to reflect enhanced endothelial-derived
NO bioavailability.
Simple correlation coefficients were used to examine the
relation between improvement in FMD and the change in
cholesterol levels. There were borderline significant corre-
lations between FMD and the change in triglyceride (r 5
20.24, p 5 0.04) and total cholesterol (r 5 20.21, p 5
0.066) levels, but not with the change in HDL (p 5 0.19)
or LDL (p 5 0.11) cholesterol levels.
DISCUSSION
In this study, we have demonstrated that six weeks of
treatment with the HMG-CoA reductase inhibitor atorva-
statin improves endothelial dysfunction in young subjects
with type I DM who had normal cholesterol levels. Dietary
administration of L-arginine did not have a beneficial effect
on endothelial function, in contrast to experimental models
of type I DM and to studies in hypercholesterolemic
subjects. Improvement in endothelial function in response
to atorvastatin therapy may have a favorable effect on the
progression of vascular disease in type I DM.
Role of cholesterol reduction in type I DM. The impor-
tant role of lipids in the etiology of diabetic vascular disease,
as well as a potential beneficial role for cholesterol reduc-
tion, was proposed by Joslin more than 70 years ago (40).
Since then, epidemiologic studies have confirmed the link
between cholesterol levels and cardiovascular morbidity and
mortality (41), and recent clinical trials have demonstrated
an improved outcome when lipid-lowering therapy is com-
menced in diabetic patients with established atherosclerosis
(42). In this study, we purposefully selected subjects without
grossly elevated cholesterol levels, who are likely to be
representative of the majority of young patients with type I
DM, to examine the impact of potentially complementary
therapeutic approaches on diabetic vascular disease. Ator-
vastatin improved endothelial function after just six weeks of
treatment. This rapid response is in keeping with the
improvement in resistance vessel endothelial function re-
ported in hypercholesterolemic subjects after two weeks of
treatment with simvastatin (43). Improvement in FMD was
relatively small as compared with responses seen in other
Table 3. Determinants of Change in FMD
Source df Sum of Squares Mean Square F p Value
Atorvastatin 1 28.678 28.678 5.84 0.018
L-Arginine 1 4.942 4.942 1.01 0.319
Interaction 1 7.575 7.575 1.54 0.219
Duration of diabetes 1 33.764 33.764 6.87 0.011
Baseline FMD 1 73.312 73.312 14.92 , 0.001
Error 69 338.949 4.912
Total 74 487.448
Term
Effect
Size
95% Confidence
Interval
Atorvastatin 1.26 0.22 to 2.30
L-Arginine 20.51 21.54 to 0.51
Interaction 21.28 23.35 to 0.78
Duration of diabetes 20.07 0.02 to 0.13
Baseline FMD 20.37 20.56 to 20.18
Constant 0.37 20.72 to 1.47
The upper table is the analysis of covariance matrix for the change in FMD over the six-week duration of the study. The lower
table gives the regression coefficients (effect size). Improvement in FMD was significantly associated with atorvastatin therapy,
even after taking into account the effect of baseline FMD and duration of diabetes. L-Arginine therapy had no significant benefit
on FMD and attenuated the effect of atorvastatin when given in combination.
df 5 degrees of freedom; FMD 5 flow-mediated dilation.
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risk factor groups studied previously (8). However, the wide
range of baseline FMD results seen in this study implies
that not all subjects had endothelial dysfunction, reflecting
the heterogeneous nature of endothelial dysfunction in type
I DM. Baseline FMD was significantly associated with
improvement in FMD, such that subjects with the lowest
initial FMD had substantially greater improvement after six
weeks of treatment. This may partly reflect regression to the
mean, as baseline FMD also predicted improvement in
endothelial function in the atorvastatin/placebo group (data
not shown); however, these associations may also represent
a biologically relevant effect in those subjects with the worst
vascular disease. Further studies will be needed to determine
1) whether the benefit seen after atorvastatin therapy is
restricted to specific subgroups of patients with type I DM;
2) whether the benefit is maintained or enhanced after
longer periods of treatment; and 3) the significance of these
effects on clinical cardiovascular disease.
The dose of atorvastatin used in this study was relatively
high, as we sought to determine whether the reversal of
endothelial dysfunction may be achieved within a relatively
short time frame. Interestingly, improvement in endothelial
function was not determined by baseline cholesterol level,
and there was only a borderline significant association
between the degree of cholesterol reduction and change in
FMD. This may reflect additional actions of HMG-CoA
reductase inhibitors that are independent of LDL choles-
terol reduction, per se. Recognized effects include reduction
in triglyceride levels, upregulation of endothelial NO syn-
thase expression and effects on inflammatory cell activity
(44,45), and these might be important mechanisms by
which atorvastatin improved endothelial function in our
subjects. Further studies will be needed to determine the
effective dose of atorvastatin and its mechanism of action in
restoring endothelial function in diabetes.
Role of L-arginine therapy in type I DM. After L-arginine
therapy, there was a significant increase in plasma levels, but
there was no benefit from L-arginine therapy on endothelial
function. These data extend the results of our recent study, in
which acute administration of L-arginine had no effect on
endothelial function in a similar cohort of subjects with type I
DM, and differs from the significant improvements seen in
subjects with hypercholesterolemia (8,33). These data are
consistent with fundamental differences in the pathogenesis of
endothelial dysfunction between these risk factor groups. The
mechanism by which L-arginine improves endothelial function
remains controversial (46). In hypercholesterolemia, the effects
of increased levels of endogenous competitive antagonists of
NO synthase might be overcome by exogenous L-arginine
(47). Few data have been published on levels of these antago-
nists in type I DM, but our results suggest L-arginine levels are
not the rate-limiting factor in the synthesis of NO. An
alternative explanation may be that additional abnormalities of
the endothelium or vascular smooth muscle limited a beneficial
effect of L-arginine. However, L-arginine therapy was not able
to enhance endothelial function in our subjects, even when
other vascular abnormalities were improved after atorvastatin
therapy. Finally, recent data have indicated that endothelium-
dependent dilation in response to L-arginine may partly be a
humoral response mediated by release of insulin (48). This
would preclude benefit in patients with type I DM, in whom
endogenous insulin secretion is absent. There was a trend
toward a reduction of the effect of atorvastatin in subjects who
also received L-arginine. Although this interaction did not
reach statistical significance, the power to detect such an effect
is reduced in this small group, and it is possible that L-arginine
has a deleterious effect on endothelial function in diabetes. This
will have implications for its generalized use as an antiathero-
genic agent (49) and highlights the need to specifically identify
which patient subgroups are likely to benefit from such novel
therapies.
Conclusions. Cardiovascular risk in type I DM remains
high, despite improvements in the management of insulin
deficiency and glycemic control (1,50). The process of
atherosclerosis, manifested by abnormal conduit artery en-
dothelial function, begins early in type I DM, even in the
absence of clinical evidence of nephropathy. We have shown
that, at this early stage, endothelial dysfunction in young
patients with type I DM can be ameliorated by treatment
with atorvastatin. In contrast, treatment with L-arginine had
no significant benefit, and further studies will be required to
determine its role in preventing the progression of vascular
disease. Our results suggest that treatment with HMG-
CoA-reductase inhibitors from an early age and at lower
levels of cholesterol than presently recommended in the general
population may be indicated in order to slow the progres-
sion of atherosclerosis to clinical cardiovascular disease.
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